Journal Watch · Blood · 2026

The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma.

This trial was registered at www.clinicaltrials.gov as #NCT05759793 and #NCT05219721.

Pan M, Wang D, Xu J et al.Blood3 min readPharma relevance 75/100

DOI: 10.1182/blood.2025030559PMID: 41118600Study type: randomised / controlled clinical trial

TL;DR

This trial was registered at www.clinicaltrials.gov as #NCT05759793 and #NCT05219721.

Key findings

  • No cerebellar toxicities or treatment-related deaths were reported.
  • These findings support that RD118 is a highly effective and safe therapeutic option for heavily pretreated R/R MM.
  • This trial was registered at www.clinicaltrials.gov as #NCT05759793 and #NCT05219721.

Numbers at a glance (from the abstract)

94.4%72.2%85.7%95%82.1%93.3%88.9%or 3.0

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Among the 7 patients previously exposed to BCMA-directed CAR-T therapy, ORR reached 85.7%. Median progression-free survival (PFS) was 18.2 months (95% confidence interval, 14.4 to not estimable), with 12-month PFS and overall survival rates of 82.1% and 93.3%, respectively. Cytokine release syndrome occurred in 88.9% of the patients, primarily grade 1 to 2. One patient developed grade 3 immune effector cell-associated neurotoxicity, which resolved within 72 hours.

Full abstract (original)

Background: <h4>Abstract</h4>GPRC5D has emerged as a promising therapeutic target in relapsed/refractory multiple myeloma (R/R MM), particularly following progression after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapies. RD118 is a novel CAR-T therapy incorporating a fully human single-domain antibody fragment targeting GPRC5D. In this phase 1 study, 18 R/R patients (17 with MM and 1 with a history of primary plasma cell leukemia) received a single infusion of RD118 at 1.0 × 106, 2.0 × 106, or 3.0 × 106 CAR+ T cells per kg. At a median follow-up of 17.0 months, the overall response rate (ORR) was 94.4%, including 72.2% complete or stringent complete responses.

What they did: Among the 7 patients previously exposed to BCMA-directed CAR-T therapy, ORR reached 85.7%. Median progression-free survival (PFS) was 18.2 months (95% confidence interval, 14.4 to not estimable), with 12-month PFS and overall survival rates of 82.1% and 93.3%, respectively. Cytokine release syndrome occurred in 88.9% of the patients, primarily grade 1 to 2. One patient developed grade 3 immune effector cell-associated neurotoxicity, which resolved within 72 hours.

Results & conclusions: No cerebellar toxicities or treatment-related deaths were reported. These findings support that RD118 is a highly effective and safe therapeutic option for heavily pretreated R/R MM. This trial was registered at www.clinicaltrials.gov as #NCT05759793 and #NCT05219721.

Abstract © the authors / Blood (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1182/blood.2025030559 · PubMed 41118600.

Why it matters for pharma & biotech

  • Directly relevant to teams in cell therapy (CAR-T / engineered cells) — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: cell therapy (CAR-T / engineered cells)

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Blood study find?

This trial was registered at www.clinicaltrials.gov as #NCT05759793 and #NCT05219721.

What type of study is this?

It is a randomised / controlled clinical trial, published in Blood in 2026. Among the 7 patients previously exposed to BCMA-directed CAR-T therapy, ORR reached 85.7%.

Where can I read the original paper?

The original is at the publisher via DOI 10.1182/blood.2025030559. PubMed ID: 41118600. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Pan M, Wang D, Xu J et al.. The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma.. Blood (2026). DOI: 10.1182/blood.2025030559.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-fully-human-anti-gprc5d-car-t-cell-therapy-rd118-induces-durable-rem-030559/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides